INTRODUCTION
Within the last decade, the role of complement-derived anaphylatoxins, i.e., C3a and C5a in causing smooth muscle contraction and histamine release from basophils and mast cells has come into focus. Partial purification of human C3a and C5a from compelement-activated serum demonstrated that C3a (1) 27 April 1979. 804 contract guinea pig ileum and enhance vascular permeability in guinea pig skin. The addition of C3a to guinea pig ileum produced tachyphylaxis to C3a but not to C5a or histamine (2) . Likewise C5a induced smooth muscle contraction-produced tachyphylaxis to C5a and not to C3a or histamine, reflecting the likelihood that each of these agents acted on separate receptors (2) .
Recently, several studies have emphasized that C5a seemed to be the major anaphylatoxin-producing basophil histamine release after complement activation with immune complexes or zymosan (3) (4) (5) (6) (7) . In this paper, we have demonstrated histamine release from human basophil granulocytes by purified human C3a and the synthetic COOH-terminal peptides based on the structure of C3a, a pentapeptide, Leu-Gly-Leu-AlaArg (5R),1 and an octapeptide, Ala-Ala-Ala-Leu-GlyLeu-Ala-Arg (8R). Furthermore, attempts were made to identify the cells to which '25I-C3a or 1251-C5a were bound using autoradiography.
METHODS
Preparation of leukocytes. Venous blood was collected from human donors and leukocytes were separated by dextran sedimentation (8) . Mononuclear cells and neuitrophil granulocyte fractions were obtained from whole blood by differential centrifugation on a Ficoll-Hypaque layer (9) (Ficoll, Pharmacia Fine Chemicals, Inc., Piscataway, N. J.; Hypaquie, Winthrop Laboratories, New York).
Purified anaphylatoxin and peptides. C3a and C5a were purified from fresh human serum by the methods previously described (10, 11) . Purified C3a and C5a gave a single band in polyacrylamide gel electrophoresis. Antiserum specific for C3a and C5a were prepared in rabbits as described (10) .
C3ades ArgI and C5ades Argl were prepared as described (11) .
'Abbreviations used itl this paper: 5R, Leu-Gly-Leu-Ala-COOH-termriinal octapeptide (8R)2 and pentapeptide (5R)2 of C3a were synthesized by a solid-phase method as described (12) .
Both C3a and C5a were labeled with 125I by either the solid-phase lactoperoxodase method (13) or the acylating agent technique (14) . Specific radioactivity of the preparations varied beteen 13 Because a part of C3a may be degraded by radioiodination, the proportion of 125I-C3a bindable to leukocyte was estimated by adding 106 to 4 x 107 leukocytes to 1 ng 1251-C3a. The results showed that 15-50% of total radioactivity in the preparations were bindable to leukocytes. In addition, the integrity of the 125I-C3a and 1251-C5a binding to rabbit anti-C3a and -C5a sera was tested with each labeled preparation and varied from 20 to 60% binding. Preparations with <20% binding to specific antisera were discarded.
Autoradiography. Leukocytes (5 x 106/ml) suspended in EDTA Tris A buffer were incubated with an appropriate concentration of 125I-C3a (56 uCi/.ug) 125I-C5a (60 ,Ci/,Lg) at 37°C for 30 min. 1 ml of the cell suspension was layered on 3 ml of heat-inactivated fetal calf serum and centrifuged at 200 g for 10 min. Cells in the pellet were washed with the same buffer and the smears of the cells were stained with Wright stabilized staining solution. Autoradiographs of the smears were performed as described (16 After incubation, the volume of each tube was adjusted to 1.0 ml, and centrifuged to obtain the supernate. The histamine content in the supernate was measured by the automated technique of Siraganian (17) .
Kinetic studies of histamine release. Multiple reaction tubes containing 0.1 ml of an appropriate concentration of C3a or anti-IgE and 0.1 ml Tris ACM were assembled as described above. The reaction was terminated at various time intervals by the addition of 0.2 ml ice-cold 0.02 M EDTA Tris A buffer, and the reaction tubes were moved to an ice bath. The final volume in the tubes was adjusted to 1.0 ml with cold buffer, and the supernates were obtained for histamine analysis.
RESULTS
Binding of 1251-C3a and 125I-C5a to human leukocytes. To demonstrate the binding of C3a and C5a to human leukocytes, 2-4 ng of 1251-C3a or 4 ng of t251-C5a was added to a suspension of leukocytes that contained 2.5 x 106 nucleated cells. The final concentration of 125I-C3a and 1251-C5a in the cell suspension was 0.22-0.41 nM and 0.36 nM, respectively. After incubation at 37°C for 30 min, the cells were centrifuged in a microfuge and radioactivity bound to the cell pellets was determined. The results showed that approximately 2% of the added radioactivity in 1251-C3a and 5% of the added 1251-C5a were bound to the leukocytes (Table I) . When mononuclear cells and neutrophil fractions, (both containing 2.5 x 106 cells), were incubated in higher concentration of 125I-C3a (up to 4 nM), 1251-C3a bound to the mononuclear cells was similar to that bound to the granulocytes (Fig. 1A) . When the same cell fractions were incubated in 125I-C5a (up to 1.7 nM), however, counts per minute bound to the neutrophil fraction was 7-10 times greater than counts per minute bound to mononuclear cells (Fig. 1B) suggesting a higher affinity of C5a for neutrophils. The kinetics of C3a-induced histamine release were similar to those described for C5a-induced release and quite different from anti-IgE-mediated release (Fig. 6) . Release was rapid, being complete at the first time point studied (1 min). In contrast, the response of anti-IgE is sigmoid, with a short lag followed by a release process, which proceeds relatively slowly for the next 20-30 min. Release was definitely greater at 37°C as opposed to 25°C; there is some conflict on this point with respect to C5a release reported by Siraganian and Hook (7) and Grant et al. (6) .
Histamine release with COOH-terminal peptides of C3a, i.e., 5R and 8R. The activity of the synthetic COOH-terminal peptides, 5R and 8R, was studied using a donor whose leukocytes demonstrate >50% histamine release upon exposure to C3a. In the preliminary experiments, various concentrations of 5R and 8R were incubated with cells in the presence of 0.01 M EDTA Tris-A buffer at 37°C for 45 min, and the supernates ofthe tubes as well as various concentrations of 5R and 8R in the buffer were analyzed. The results indicated that the peptides were not fluorescent themselves and did not interfere with the fluorometric assay. When the same leukocytes were incubated with 5R or 8R in Tris ACM buffer, both SR and 8R released a significant amount of histamine from the cells. In this experiment, the concentration of C3a for 50% histamine release was 9 AM, whereas the concentration of SR and 8R required for 50% histamine release was 80 and 50 AM, respectively (Fig. 7 ). It appears that on a molar basis 5R was one-tenth, and 8R was one-fifth as active as C3a in inducing histamine release from human leukocytes.
Inhibition of 1251-C3a binding to leukocytes by C3a, 5R, and 8R. Because the results of histamine release indicated that SR and 8R are capable ofreacting with basophils, the ability of the peptides to inhibit the binding of 125I-C3a to leukocytes was examined. Aliquots of a leukocyte suspension, which contained 2.5 x 106 nucleated cells, were mixed with C3a, 8R, or SR of varying concentrations. After incubation at 37°C for 30 min, 2 ng of 1251-C3a was added to each tube, which was incubated at 37°C for another 30 min with constant shaking. The concentration of "bindable 125I-C3a" in the final cell suspension was 0.066 nM. It is apparent in Fig. 8 that both 5R and 8R inhibited the binding of 1251-C3a. Quantitatively, however, the COOH-terminal peptides were much less active than C3a. Thus, 50% inhibition of the binding was achieved by 14-15 MM of 8R, or 45-50 MM of SR, whereas as low as 0.7-1 nM of unlabeled C3a was sufficient for 50% inhibition. Similar experiments using leukocytes from a different donor confirmed that molar concentrations of SR and 8R required for 50% inhibition were m6,000 and 2,000 times as high as the concentration of C3a for 50% inhibition.
DISCUSSION
The biological activity of the comnplement-derived anaphylatoxins has been appreciated for almost 80 yr. Only recently, however, has it been recognized that the components responsible for this activity are split Human C3a Leukocyte Binding and Histamine Release E p B FIGuRE 3 Autoradiograph of leukocytes treated with 125I-C3a (56 ,Ci/,ug) or 125I-C5a (60 ,Ci/,ug). Focus was directed on cells for morphology. Basophil was inserted in lower left for photomicrograph clarity; B = basophil, E = eosinophil, P = polymorphonuclear leukocyte.
products of C3 and C5, designated C3a and C5a (1, 2) . In this paper we have been concerned with the binding of highly purified C3a or CSa to the cells in human blood particularly and with the ability of C3a to release histamine from human basophils. Histamine release with partially purified C5a has been previously reported (7) .
Both C3a and C5a bind specifically to human leukocytes and unlabeled C3a blocks the binding of 125I-C3a but not that of 1251-C5a. These results indicate that the two anaphylatoxins recognize and combine with different leukocyte receptors. An interesting test of specificity was that the removal of the COOHterminal arginine of C3a led to a totally inactive product that did not inhibit the binding of intact radiolabeled C3a. The des Arg derivative of CSa, on the other hand, retained some ability to block the binding of intact C5a. Thus, the terminal, basic amino acid is responsible, at least to some degree, for the binding of C5a to leukocytes and is essential for the binding of C3a. This behavior was recently noted (18) for the binding of C5a and C5adesA,g to purified human neutrophils.
Anaphylatoxin binding was further pursued by autoradiography with 1251-labeled C3a and C5a. The two anaphylatoxins were quite diffent in this respect as well: C3a bound preferentially to eosinophils and to basophils, with lesser binding to neutrophils. On receptor occupancy leads to histamine release. It seems likely that further studies can define the parameters necessary to assess biological significance.
